Viral targets for vaccines against COVID-19

[1]  Shibo Jiang,et al.  Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2022, PloS one.

[2]  P. Shanley,et al.  SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 , 2021, Evidence-Based Practice.

[3]  D. Burton,et al.  Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2021, Nature Communications.

[4]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[5]  Yong-tang Zheng,et al.  S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates , 2020, Nature Communications.

[6]  E. Cesse,et al.  Lessons from COVID-19 , 2021, Revista Brasileira de Saúde Materno Infantil.

[7]  Elisabeth Mahase.  Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week , 2020, BMJ.

[8]  K. Chu,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2020, The Lancet Infectious Diseases.

[9]  Elisabeth Mahase.  Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients , 2020, BMJ.

[10]  W. Chen,et al.  Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Skovronsky,et al.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[12]  J. Diedrich,et al.  Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate , 2020, Science.

[13]  Shibo Jiang,et al.  Learning from the past: development of safe and effective COVID-19 vaccines , 2020, Nature Reviews Microbiology.

[14]  Wenling Wang,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.

[15]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[16]  I. Wilson,et al.  Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies , 2020, Biochemical and Biophysical Research Communications.

[17]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[18]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[19]  D. Yokoe,et al.  Treatment of immunocompromised COVID‐19 patients with convalescent plasma , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[20]  D. Burton,et al.  Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2020, bioRxiv.

[21]  Xueqin Huang,et al.  Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19 , 2020, bioRxiv.

[22]  P. Gallian,et al.  Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 , 2020, Blood.

[23]  Shibo Jiang,et al.  Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2 , 2020, Expert opinion on therapeutic targets.

[24]  Oliver C. Grant,et al.  Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition , 2020, Scientific Reports.

[25]  X. Xie,et al.  Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy , 2020, Cell.

[26]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[27]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[28]  D. Lauffenburger,et al.  Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters , 2020, Nature Medicine.

[29]  A. Gintsburg,et al.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.

[30]  V. Shinde,et al.  Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.

[31]  M. Halloran,et al.  Zika virus infection enhances future risk of severe dengue disease , 2020, Science.

[32]  J. Bloom,et al.  Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate , 2020, Journal of Clinical Microbiology.

[33]  E. Walsh,et al.  RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study , 2020, medRxiv.

[34]  N. Patel,et al.  NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.

[35]  Lisa E. Gralinski,et al.  A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.

[36]  J. Bloom,et al.  Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate , 2020, medRxiv.

[37]  Yongli Yang,et al.  Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.

[38]  N. Sofat,et al.  Immunomodulatory Drugs in the Management of SARS-CoV-2 , 2020, Frontiers in Immunology.

[39]  Lisa E. Gralinski,et al.  Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.

[40]  E. Walsh,et al.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.

[41]  J. Diedrich,et al.  Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate , 2020, bioRxiv.

[42]  Quanxin Long,et al.  Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[43]  Shuwen Liu,et al.  Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.

[44]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[45]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[46]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[47]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[48]  Yuquan Wei,et al.  A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.

[49]  Rebecca J. Loomis,et al.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[50]  D. Lauffenburger,et al.  Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[51]  Ilya J. Finkelstein,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[52]  Xia Zhong,et al.  A Thermostable mRNA Vaccine against COVID-19 , 2020, Cell.

[53]  J. Sodroski,et al.  Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.

[54]  S. Rawson,et al.  Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.

[55]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[56]  Y. Hu,et al.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.

[57]  G. Gao,et al.  Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients , 2020, Immunity.

[58]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[59]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[60]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[61]  S. Perlman,et al.  Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.

[62]  W. Cao,et al.  High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects , 2020, Frontiers in Immunology.

[63]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice , 2020, bioRxiv.

[64]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[65]  G. Gao,et al.  A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS , 2020, Cell.

[66]  John P. Moore,et al.  SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds. , 2020, Journal of virology.

[67]  M. Nussenzweig,et al.  Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.

[68]  U. Qimron.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[69]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[70]  J. Dye,et al.  Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.

[71]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[72]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[73]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[74]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[75]  I. Tizard.  Vaccination against coronaviruses in domestic animals , 2020, Vaccine.

[76]  Rongchang Chen,et al.  Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment , 2020, Cell.

[77]  S. Khurana,et al.  Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits , 2020, Science Translational Medicine.

[78]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[79]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[80]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[81]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[82]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[83]  Daniel W. Kulp,et al.  Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.

[84]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[85]  Xiangxi Wang,et al.  Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection , 2020, bioRxiv.

[86]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[87]  Shaun Rawson,et al.  Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.

[88]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[89]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[90]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[91]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[92]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[93]  Daniel Wrapp,et al.  Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.

[94]  Jun Yuan,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[95]  B. Liu,et al.  Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020 , 2020, Emerging infectious diseases.

[96]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[97]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[98]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[99]  Hongzhu Cui,et al.  Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins , 2020, Viruses.

[100]  Guihua Zhang,et al.  A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019 , 2020, Journal of medical virology.

[101]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[102]  C. B. Wang.  [Analysis of low positive rate of nucleic acid detection method used for diagnosis of novel coronavirus pneumonia]. , 2020, Zhonghua yi xue za zhi.

[103]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[104]  B. Graham,et al.  Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation , 2020, bioRxiv.

[105]  G. Gao,et al.  Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry , 2020, Emerging microbes & infections.

[106]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[107]  Barney S. Graham,et al.  Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD , 2019, Cell Reports.

[108]  P. Niu,et al.  Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein , 2019, Nature Communications.

[109]  T. Takano,et al.  Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route , 2019, The Journal of veterinary medical science.

[110]  Jingwei Huang,et al.  Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain , 2019, Viruses.

[111]  Linqi Zhang,et al.  Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein , 2018, Cell Reports.

[112]  Jun Chang,et al.  Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles , 2018, Front. Immunol..

[113]  F. Luo,et al.  Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine , 2018, Virologica Sinica.

[114]  K. Stiasny,et al.  The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design , 2017, EMBO reports.

[115]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[116]  Yi Shi,et al.  Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.

[117]  John P. Moore,et al.  Native‐like Env trimers as a platform for HIV‐1 vaccine design , 2017, Immunological reviews.

[118]  G. Wong,et al.  Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice , 2016, Antiviral Research.

[119]  G. Gao,et al.  The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection , 2016, Vaccine.

[120]  G. Gao,et al.  T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.

[121]  R. Baric,et al.  Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.

[122]  Jing Xie,et al.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.

[123]  Seza Inal.  Middle East Respiratory Syndrome-Coronavirus (MERSCoV) Infection , 2016 .

[124]  G. Gao,et al.  Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond , 2015, Trends in Microbiology.

[125]  Fang Li,et al.  Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies , 2014, Journal of Virology.

[126]  Shibo Jiang,et al.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.

[127]  Fu-Tong Liu,et al.  Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.

[128]  R. Baric,et al.  Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.

[129]  Shibo Jiang,et al.  A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2013, PloS one.

[130]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[131]  P. Hotez,et al.  Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome , 2012, Expert review of vaccines.

[132]  R. Couch,et al.  Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PLoS ONE.

[133]  R. Couch,et al.  Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PloS one.

[134]  M. Ryser-Degiorgis.  Other coronavirus infections , 2012 .

[135]  Lisa E. Gralinski,et al.  A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.

[136]  J. Peiris,et al.  Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.

[137]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[138]  Christopher D. Paddock,et al.  Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.

[139]  T. Takano,et al.  Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. , 2008, The Journal of veterinary medical science.

[140]  S. Inoue,et al.  Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV1 , 2008, The Journal of Immunology.

[141]  Shibo Jiang,et al.  Development of subunit vaccines against severe acute respiratory syndrome. , 2008, Drugs of today.

[142]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[143]  M. Peiris,et al.  Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro , 2006, Vaccine.

[144]  R. Johnston,et al.  Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants , 2006, PLoS medicine.

[145]  William C. Hwang,et al.  Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R* , 2006, Journal of Biological Chemistry.

[146]  G. Gao,et al.  Screening and Identification of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific CTL Epitopes1 , 2006, The Journal of Immunology.

[147]  Chi-Ju Chen,et al.  Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates , 2006, Vaccine.

[148]  Y. Zhang,et al.  Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine , 2005, Vaccine.

[149]  T. Hohdatsu,et al.  A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies , 2005, Archives of Virology.

[150]  P. Talbot,et al.  Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody , 2005, Archives of Virology.

[151]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[152]  D. Dimitrov,et al.  Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain , 2004, Biochemical and Biophysical Research Communications.

[153]  G. Gao,et al.  Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors , 2004, Biochemical and Biophysical Research Communications.

[154]  E. Collisson,et al.  Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. , 2000, Developmental and comparative immunology.

[155]  Pamela G. Guren,et al.  Candidates , 1982 .

[156]  R. Zinkernagel,et al.  Neutralizing antiviral B cell responses. , 1997, Annual review of immunology.

[157]  H. Vennema,et al.  Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization , 1990, Journal of virology.

[158]  K. Nakanaga,et al.  Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice , 1986, Journal of virology.

[159]  F. Scott,et al.  Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever☆ , 1981, Comparative Immunology, Microbiology and Infectious Diseases.

[160]  SB Halstead,et al.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.

[161]  A. Allison,et al.  Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection , 1977, The Journal of experimental medicine.